Achillion Pharmaceuticals Inc. (ACHN)’s Financial Results Comparing With Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)

Since Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achillion Pharmaceuticals Inc. 4 -0.34 125.56M -0.50 0.00
Deciphera Pharmaceuticals Inc. 35 -0.34 20.18M -3.40 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Achillion Pharmaceuticals Inc. and Deciphera Pharmaceuticals Inc.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Achillion Pharmaceuticals Inc. 2,943,686,406.90% -25.2% -24.2%
Deciphera Pharmaceuticals Inc. 57,329,545.45% -43.4% -38.7%

Liquidity

19.7 and 19.7 are the respective Current Ratio and a Quick Ratio of Achillion Pharmaceuticals Inc. Its rival Deciphera Pharmaceuticals Inc.’s Current and Quick Ratios are 9.6 and 9.6 respectively. Achillion Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Deciphera Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Achillion Pharmaceuticals Inc. and Deciphera Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achillion Pharmaceuticals Inc. 0 0 0 0.00
Deciphera Pharmaceuticals Inc. 0 0 2 3.00

Achillion Pharmaceuticals Inc.’s consensus target price is $5, while its potential upside is 36.24%. On the other hand, Deciphera Pharmaceuticals Inc.’s potential upside is 84.33% and its consensus target price is $60. The information presented earlier suggests that Deciphera Pharmaceuticals Inc. looks more robust than Achillion Pharmaceuticals Inc. as far as analyst view.

Institutional and Insider Ownership

Achillion Pharmaceuticals Inc. and Deciphera Pharmaceuticals Inc. has shares held by institutional investors as follows: 83% and 60.9%. Insiders held 0.15% of Achillion Pharmaceuticals Inc. shares. On the other hand, insiders held about 0.2% of Deciphera Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achillion Pharmaceuticals Inc. 22.5% 60.95% 51.55% 103.23% 66.42% 177.36%
Deciphera Pharmaceuticals Inc. 0.87% -7.92% -3.62% -16.13% -34.17% 5.29%

For the past year Achillion Pharmaceuticals Inc. was more bullish than Deciphera Pharmaceuticals Inc.

Summary

On 8 of the 11 factors Achillion Pharmaceuticals Inc. beats Deciphera Pharmaceuticals Inc.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.